Exscientia Plc ADR (NASDAQ: EXAI) stock jumped 2.18% on Friday to $6.10 against a previous-day closing price of $5.97. With 0.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.62 million shares. The 52-week range on EXAI shows that it touched its highest point at $11.52 and its lowest point at $4.09 during that stretch. It currently has a 1-year price target of $9.50. Beta for the stock currently stands at 0.70.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EXAI was up-trending over the past week, with a rise of 15.97%, but this was up by 17.76% over a month. Three-month performance dropped to -6.30% while six-month performance rose 0.99%. The stock lost -12.36% in the past year, while it has gained 14.45% so far this year. A look at the trailing 12-month EPS for EXAI yields -1.43 with Next year EPS estimates of -1.39. For the next quarter, that number is -0.34. This implies an EPS growth rate of -18.43% for this year and -0.32% for next year.
Float and Shares Shorts:
At present, 122.96 million EXAI shares are outstanding with a float of 117.51 million shares on hand for trading. On Oct 30, 2023, short shares totaled 3.36 million, which was 2.70% higher than short shares on Sep 28, 2023. In addition to Prof. Andrew L. Hopkins DPHIL, FMEDSCI, FRSE FRSC as the firm’s Founder, CEO & Executive Director, Mr. Ben R. Taylor serves as its CFO, Chief Strategy Officer & Executive Director.
Through their ownership of 28.57% of EXAI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 3.39% of EXAI, in contrast to 18.48% held by mutual funds. As the largest shareholder in EXAI with 4.58% of the stake, Laurion Capital Management LP holds 5,627,444 shares worth 5,627,444. A second-largest stockholder of EXAI, Baillie Gifford & Co., holds 4,868,810 shares, controlling over 3.96% of the firm’s shares. Platinum Investment Management Lt is the third largest shareholder in EXAI, holding 4,395,058 shares or 3.57% stake. With a 0.72% stake in EXAI, the Pictet – Biotech is the largest stakeholder. A total of 884,056 shares are owned by the mutual fund manager. The iShares Biotechnology ETF, which owns about 0.47% of EXAI stock, is the second-largest Mutual Fund holder. It holds 573,690 shares valued at 3.1 million. St. James’s Place Unit Trust – UK holds 0.39% of the stake in EXAI, owning 478,134 shares worth 2.58 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EXAI since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With EXAI analysts setting a high price target of $11.00 and a low target of $7.00, the average target price over the next 12 months is $9.50. Based on these targets, EXAI could surge 80.33% to reach the target high and rise by 14.75% to reach the target low. Reaching the average price target will result in a growth of 55.74% from current levels.